HomeCompareFMIHX vs ABBV

FMIHX vs ABBV: Dividend Comparison 2026

FMIHX yields 16.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FMIHX wins by $56.75M in total portfolio value
10 years
FMIHX
FMIHX
● Live price
16.69%
Share price
$12.65
Annual div
$2.11
5Y div CAGR
48.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.86M
Annual income
$46,203,611.15
Full FMIHX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FMIHX vs ABBV

📍 FMIHX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFMIHXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FMIHX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FMIHX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FMIHX
Annual income on $10K today (after 15% tax)
$1,418.92/yr
After 10yr DRIP, annual income (after tax)
$39,273,069.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FMIHX beats the other by $39,252,013.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FMIHX + ABBV for your $10,000?

FMIHX: 50%ABBV: 50%
100% ABBV50/50100% FMIHX
Portfolio after 10yr
$28.48M
Annual income
$23,114,191.46/yr
Blended yield
81.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FMIHX
No analyst data
Altman Z
1.6
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FMIHX buys
0
ABBV buys
0
No recent congressional trades found for FMIHX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFMIHXABBV
Forward yield16.69%3.06%
Annual dividend / share$2.11$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.2%40.6%
Portfolio after 10y$56.86M$102.3K
Annual income after 10y$46,203,611.15$24,771.77
Total dividends collected$55.92M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FMIHX vs ABBV ($10,000, DRIP)

YearFMIHX PortfolioFMIHX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,174$2,473.92$11,550$430.00+$1.6KFMIHX
2$18,610$4,514.04$13,472$627.96+$5.1KFMIHX
3$28,745$8,832.10$15,906$926.08+$12.8KFMIHX
4$49,652$18,894.72$19,071$1,382.55+$30.6KFMIHX
5$98,332$45,204.18$23,302$2,095.81+$75.0KFMIHX
6$229,209$123,994.14$29,150$3,237.93+$200.1KFMIHX
7$645,571$400,316.94$37,536$5,121.41+$608.0KFMIHX
8$2,252,399$1,561,638.37$50,079$8,338.38+$2.20MFMIHX
9$9,956,583$7,546,515.85$69,753$14,065.80+$9.89MFMIHX
10$56,857,155$46,203,611.15$102,337$24,771.77+$56.75MFMIHX

FMIHX vs ABBV: Complete Analysis 2026

FMIHXStock

The fund invests mainly in a limited number of large capitalization (namely, companies with more than $5 billion market capitalization at the time of initial purchase) value stocks of companies listed or traded on a national securities exchange or on a national securities association, including foreign securities traded on a national securities exchange or on a national securities association. The fund is non-diversified.

Full FMIHX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FMIHX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FMIHX vs SCHDFMIHX vs JEPIFMIHX vs OFMIHX vs KOFMIHX vs MAINFMIHX vs JNJFMIHX vs MRKFMIHX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.